GLP1_NEW
Exenatide extended release plus pioglitazone 2 to 30 mg injection once weekly
EXENER_SC_2-30MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.43 (0.01 to 22.37) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Dulaglutide flexible dose injection once weekly | HR 1.55 (0.11 to 25.52) | 0.59 |